Apply for active substance renewal by the deadlines to keep products on the GB market Under the GB BPR, active substance approvals will expire unless a renewal application is submitted at least 550 days before their expiry date. The 550-day deadlines are coming up for the following active substance/product type combinations under GB BPR: 4-bromo-2-(4-chlorophenyl)-5- (trifluoromethyl)-1H-pyrrole-3-carbonitrile (Tralopyril) (CAS 122454-29-9 EC n/a) in product type 21 28 September 2023
Nonanoic acid (Pelargonic acid) (CAS 112-05-0 EC 203-931-2) in product type 2 29 March 2024 Any person, company or taskforce/consortium can support an active substance/product type combination for renewal it doesnt have to be the original supporter. Check the GB Article 95 List to see who the original supporters were. If a renewal application is not submitted for the above active substance/product type combinations under GB BPR, the approvals will expire. This means the active substances can no longer be used in biocidal products of the relevant product types in GB. Submit a notification by the deadline to keep active substances in the GB Review Programme HSE has published an open invitation to provide an opportunity for a person, company or task force/consortium to notify an intention to take up or take over the role of participant in the GB Review Programme for the following active substance/product type combination. Anyone wishing to support one of the active substance/product type combinations listed below in GB will need to submit a notification to HSE by the following deadline: Peanut Butter (CAS n/a EC n/a) in product type 19 14 March 2024 If a notification to take over the role of participant is not received, this active substance/product type combination will be subject to a GB non-approval decision. Biocidal products containing active substances with GB non-approval decisions for the relevant product types will have to be removed from the GB market. HSE will provide separate updates on these where relevant. If you are aware of any disproportionate negative effects that are likely to arise from the non-approval of any of the active substance/product type combinations listed above, please contact us. |